Patent · US Active

Inactivation of genes of the MEP pathway

US7875279B2 · kind B2 · utility

0Cited by

0References

3Claims

0Family size

Assignee

Bioagency AG · DE

Inventors

Hassan Jomaa · Gießen, DE
Matthias Eberl · Schweinhub, DE
Boran Altincicek · Gießen, DE

Key dates

Filing date	Apr 13, 2002
Grant date	Jan 25, 2011
Priority date	—
Expiry date	Jul 13, 2026

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to cells and organisms as well as to methods for producing said cells and organisms, according to which intermediates of the mevalonate-independent pathway for isoprenoid biosynthesis (MEP pathway) are enriched by deleting or inactivating genes. The derivatives can also be enriched by using enzyme inhibitors. The enriched intermediates may be used as substrates in enzyme activity tests. The inventive cells and organisms and the enriched intermediates can further be used in the production of medicaments.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.